A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
Study Identifier
M16-904
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Protocol
Available Language(s): English
Statistical Analysis Plan
Available Language(s): English
Plain Language Summary
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
Phase 3
Sex
Female & Male
Age
2 - 11 Years
Protocol Summary
The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have been previously treated with a GnRHa.
Study Locations
Location
Status
Location
Pediatric Endocrinology Associates /ID# 200629
Long Beach, California, United States, 90806-1651
Status
Not applicable
Location
Rady Children's Hospital San Diego /ID# 202491
San Diego, California, United States, 92123
Status
Not applicable
Location
Children's Hospital Colorado /ID# 201645
Aurora, Colorado, United States, 80045
Status
Not applicable
Location
Pediatric Endocrine Associates /ID# 201089
Greenwood Village, Colorado, United States, 80111
Status
Not applicable
Location
Nemours Children's Health System /ID# 201331
Jacksonville, Florida, United States, 32207
Status
Not applicable
Location
Arnold Palmer Hospital /ID# 201624
Orlando, Florida, United States, 32806
Status
Not applicable
Showing {first} - {last} of {total} Results